



CCLG guideline on the management of chemotherapy induced nausea and vomiting

March 2018

CCLG does not sponsor nor indemnify the treatment detailed herein. These clinical guidelines are provided by the CCLG Supportive Care Group to inform and for use at the sole discretion of treating clinicians who retain professional responsibility for their actions and treatment decisions. Treatment recommendations are based on current best practice and not what is necessarily proposed for any forthcoming clinical trial.

TABLE OF CONTENTS

Executive summary	3
Introduction	3
Methods.....	4
CCLG Group.....	4
Recommendations: over-riding principles.....	5
Prophylaxis: very highly emetogenic chemotherapy.....	6
Prophylaxis: highly emetogenic chemotherapy.....	6
Prophylaxis: moderately emetogenic chemotherapy.....	7
Prophylaxis: low emetogenic chemotherapy.....	7
Prophylaxis: minimally emetogenic chemotherapy.....	7
Breakthrough nausea or vomiting	7
Refractory nausea or vomiting.....	8
Anticipatory nausea or vomiting.....	8
Delayed nausea & vomiting	8
Discharge medication:	8
Source Guidelines:	9
References to Tools:	9
Other References:	9
Figure 1. site of actions of anti-emetics.....	10
Table. 1. site of actions of anti-emetics	10
Table 2. overall approach Flow-chart	11
Table 3. emetogenicity of chemotherapy (Example).....	12
Table 4. Anti-emetics recommended dosages and usage instructions (<i>alphabetical</i>)	16

EXECUTIVE SUMMARY

The CCLG supportive care group have compiled this national framework document based on excellent international guidelines with the aim of providing a comprehensive overview which may be taken to standardize therapy across CCLG Centers for the management of chemotherapy induced nausea and vomiting.

INTRODUCTION

Chemotherapy-induced nausea and vomiting (CINV) are said to be the most documented distressing side-effects of childhood cancer treatment, potentially influencing compliance with future treatments if not managed appropriately (Wood et al. 2015). Managed incorrectly, they can lead to physical problems such as anorexia, malnutrition and dehydration, plus psychological complications that in turn may lead to anticipatory nausea and vomiting (Rodgers et al. 2012; Dewan, Singhal and Harit, 2010).

Nausea and vomiting are reflexes initiated by the body to expel toxic substances from the stomach and intestine (Navari, 2013). Emesis is co-ordinated by the vomiting Centre situated in the medulla which receives input from the chemoreceptor trigger zone (CTZ) found in the area postrema and is outside of the blood-brain barrier. It is stimulated by circulating toxins or drugs such as chemotherapy. The CTZ possesses many 5HT₃ receptors, NK1 receptors and Dopamine receptors (D2). The vomiting Centre is stimulated by drugs, smells, sights, emotions etc. as well as G.I input. CINV may result from chemo or CSF fluid acting directly on the CTZ, in the vomiting Centre but chemotherapy may also induce the release of serotonin and substance P from cells within the gastric mucosa.

The different stages of CINV are acute (0-24hrs after 1st dose); delayed (24hrs-5 days post chemotherapy) and anticipatory (prior to the start of chemotherapy). Physiological differences exist in acute and delayed CINV. Acute is mediated by the neurotransmitter serotonin, whereas delayed is mediated by substance P. Therefore optimal management of CINV may require targeting the peripheral pathways with a 5HT₃ receptor antagonist and the central pathway with an NK1 receptor.

The provision of adequate preventative and responsive anti-nausea and vomiting therapies is key in all centers where children are treated with chemotherapy. The different centres have traditionally used their own guidelines, but not developed according to the recommendations of the NICE Guideline Methodology. An international collaboration, centred in the Canadian POGO group, developed a series of detailed evidence-based guidelines for the management of different phases of treatment-related nausea and vomiting. This document details the recommendations and explanatory notes where necessary to explain different decisions from the Canadian-led panel. The research and main linking explanations are found in the accompanying guideline documents.

METHODS

This guideline is a national framework document for local implementation. It relies on the work undertaken by the Canadian-led POGO group who developed three clinical practice guidelines for the prevention and management of chemotherapy-induced nausea and vomiting (CINV) in children.

The POGO group convened an international guideline panel to create a clinical practice guideline based on accepted best-practice methods (similar to those used by NICE). The group undertook a series of focused systematic reviews addressing management question in the prevention of CINV, and the treatment of breakthrough, refractory and anticipatory CINV. They then summarized this evidence and debated it, placing it in clinical context and developing recommendations. The guidelines were then subject to international stakeholder review before publication.

Now all phases of the management have been completed, the CCLG Supportive Care group has undertaken to summarize and contextualize in a UK framework to provide an up to date framework for local guidelines to be developed from. This involved the summarizing of the guidelines, discussion of the recommendations made within a UK licensing context, and providing a summary guide as an example for use. Recommendations were then circulated via the CCLG Guideline Development Group panel and feedback incorporated.

The CCLG Group noted that each centre may have subtle variations on their interpretation of the evidence, some driven by local commissioning or drug procurement processes, which make cost-effectiveness decisions different and the local guideline marginally different. The CCLG Group were also very mindful of the necessarily poor quality of evidence that underlies the banding of drugs into emetogenic potential. Such data in children are drawn from small studies, often confounded by expectation and prophylactic antiemetics. As such, centre variations may occur. Centres with experience and disagreement with a classification system (such as the POGO system) are encouraged to publish their experience to support the advancement of the knowledgebase.

CCLG GROUP

The adaptation group consisted of: Dr Bob Phillips, Prof Faith Gibson, Mr. Pritesh Patel, Mrs. Eloise Neumann, Dr Amy Mitchell, Dr Geoff Shenton, Mrs. Ghazala Javid and Dr Hugh Bishop.

RECOMMENDATIONS: OVER-RIDING PRINCIPLES

CHILDREN AND YOUNG PEOPLE ABOUT TO UNDERTAKE CHEMOTHERAPY SHOULD HAVE THEIR CHEMOTHERAPY ASSESSED FOR EMETOGENICITY

Balancing the use of antiemetic against the chance of the chemotherapy causing problems is a key principle. A number of systems have been proposed; for this guideline the POGO-developed system will be used. It divides chemotherapy into four strata

- Highly emetogenic chemotherapy (HEC) includes Very highly emetogenic chemotherapy
- Moderately emetogenic chemotherapy (MEC)
- Low emetogenicity chemotherapy
- Minimal emetogenicity

CHILDREN AND YOUNG PEOPLE SHOULD HAVE THEIR SYMPTOMS OF NAUSEA AND VOMITING ASSESSED

There are a range of assessment tools for nausea and vomiting (see 'References'). These guidelines strongly advise using them within practice in order to improve patient care. No clear data supports the use of any one system over another, and with varied age ranges two scales may be preferred.

CHILDREN AND YOUNG PEOPLE ABOUT TO UNDERTAKE CHEMOTHERAPY SHOULD HAVE THEIR EMETOGENICITY-ASSESSED TREATMENT PRESCRIBED PRIOR TO CHEMOTHERAPY, ADAPTED TO THEIR OWN PERSONAL EXPERIENCE

While the evidence underpinning 'personalisation' of therapy is weak, it is common practice to use higher-level antiemetic's when a child or young person has experienced problems with nausea and/or vomiting previously. Good control is felt to reduce the chances of anticipatory, and breakthrough/refractory, nausea and vomiting in subsequent courses.

The source guidance expresses a preference for palonosetron in many areas. While this is based on current RCTs, the panel were concerned about the possible effects of recency bias (where more positive results are published more quickly) and the lack of clear cost-effectiveness. Combined with the weak evidence for the superiority of any other 5HT3 antagonist against any other, we recommend the use of a 5HT3 antagonist (ondansetron) as in the 2012 guideline.

PROPHYLAXIS: VERY HIGHLY EMETOGENIC CHEMOTHERAPY

FOR CHILDREN AND YOUNG PEOPLE RECEIVING VERY HIGHLY EMETOGENIC CHEMOTHERAPY A COMBINATION OF 5HT3 ANTAGONIST (ONDANSETRON), DEXAMETHASONE AND APREPITANT SHOULD BE PRESCRIBED UNLESS THERE IS A CONTRAINDICATION

Contraindications include

- Age < 6 months (aprepitant, see table 4)
- Contraindication to dexamethasone (e.g. steroids included in treatment protocol). Refer to table 4.
- Drug interaction with aprepitant. Refer to table 4.

FOR CHILDREN AND YOUNG PEOPLE RECEIVING VERY HIGHLY EMETOGENIC CHEMOTHERAPY WITH A CONTRAINDICATION TO APREPITANT A COMBINATION OF 5HT3 ANTAGONIST (ONDANSETRON) AND DEXAMETHASONE SHOULD BE PRESCRIBED UNLESS THERE IS A CONTRAINDICATION

Contraindications include

- Contraindication to dexamethasone (e.g. steroids included in treatment protocol)

FOR CHILDREN AND YOUNG PEOPLE RECEIVING VERY HIGHLY EMETOGENIC CHEMOTHERAPY WITH A CONTRAINDICATION TO APREPITANT AND DEXAMETHASONE RECEIVE A) ONDANSETRON OR B) 5HT3 ANTAGONIST (ONDANSETRON) AND LEVOMEPRIMAZINE OR C) 5HT3 ANTAGONIST (ONDANSETRON) AND METOCLOPRAMIDE OR D) 5HT3 ANTAGONIST (ONDANSETRON) AND NABILONE IN ADOLESCENTS.

PROPHYLAXIS: HIGHLY EMETOGENIC CHEMOTHERAPY

FOR CHILDREN AND YOUNG PEOPLE RECEIVING HIGHLY EMETOGENIC CHEMOTHERAPY A COMBINATION OF 5HT3 ANTAGONIST (ONDANSETRON) AND DEXAMETHASONE. APREPITANT SHOULD BE PRESCRIBED AT STEP 2 OR 3 UNLESS THERE IS A CONTRAINDICATION

Contraindications include

- Age < 6 months (aprepitant, refer to table 4)
- Contraindication to dexamethasone (e.g. steroids included in treatment protocol). Refer to table 4.
- Drug interaction with aprepitant. Refer to table 4.

FOR CHILDREN AND YOUNG PEOPLE RECEIVING HIGHLY EMETOGENIC CHEMOTHERAPY WITH A CONTRAINDICATION TO APREPITANT A COMBINATION OF 5HT3 ANTAGONIST (ONDANSETRON) AND DEXAMETHASONE SHOULD BE PRESCRIBED UNLESS THERE IS A CONTRAINDICATION

Contraindications include

- Contraindication to dexamethasone (e.g. steroids included in treatment protocol)

FOR CHILDREN AND YOUNG PEOPLE RECEIVING HIGHLY EMETOGENIC CHEMOTHERAPY WITH A CONTRAINDICATION TO APREPITANT AND DEXAMETHASONE RECEIVE A) 5HT3 ANTAGONIST (ONDANSETRON) OR B) 5HT3 ANTAGONIST (ONDANSETRON) AND LEVOMEPRIMAZINE OR C) 5HT3 ANTAGONIST (ONDANSETRON) AND METOCLOPRAMIDE OR D) 5HT3 ANTAGONIST (ONDANSETRON) AND NABILONE IN ADOLESCENTS.

This group in particular have very weak evidence to guide a selection of therapies and require further research.

PROPHYLAXIS: MODERATELY EMETOGENIC CHEMOTHERAPY

FOR CHILDREN AND YOUNG PEOPLE RECEIVING MODERATELY EMETOGENIC CHEMOTHERAPY A COMBINATION OF 5HT3 ANTAGONIST (ONDANSETRON) AND DEXAMETHASONE SHOULD BE PRESCRIBED UNLESS THERE IS A CONTRAINDICATION

Contraindications include

- Contraindication to dexamethasone (e.g. steroids included in treatment protocol). See table 4.

FOR CHILDREN AND YOUNG PEOPLE RECEIVING MODERATELY EMETOGENIC CHEMOTHERAPY WITH A CONTRAINDICATION TO DEXAMETHASONE A COMBINATION OF 5HT3 ANTAGONIST AND APREPITANT SHOULD BE PRESCRIBED UNLESS THERE IS A CONTRAINDICATION

Contraindications include

- Age < 6 months
- Drug interaction with aprepitant, see table 4.

FOR CHILDREN AND YOUNG PEOPLE RECEIVING MODERATELY EMETOGENIC CHEMOTHERAPY WITH A CONTRAINDICATION TO APREPITANT AND DEXAMETHASONE RECEIVE A) ONDANSETRON OR B) 5HT3 ANTAGONIST (ONDANSETRON) AND LEVOMEPRIMAZINE OR C) 5HT3 ANTAGONIST (ONDANSETRON) AND METOCLOPRAMIDE OR D) 5HT3 ANTAGONIST (ONDANSETRON) AND NABILONE IN ADOLESCENTS.

PROPHYLAXIS: LOW EMETOGENIC CHEMOTHERAPY

FOR CHILDREN AND YOUNG PEOPLE RECEIVING MODERATELY EMETOGENIC CHEMOTHERAPY A 5HT3 ANTAGONIST (ONDANSETRON) SHOULD BE PRESCRIBED

PROPHYLAXIS: MINIMALLY EMETOGENIC CHEMOTHERAPY

FOR CHILDREN AND YOUNG PEOPLE RECEIVING MINIMALLY EMETOGENIC CHEMOTHERAPY NO ROUTINE PROPHYLAXIS SHOULD BE PRESCRIBED

BREAKTHROUGH NAUSEA OR VOMITING

Breakthrough refers to the reoccurrence of significant nausea or vomiting after a period of acceptable control. Should a child or young person experience this, a 'next level up' approach to prophylaxis should be strongly considered on subsequent cycles.

FOR CHILDREN AND YOUNG PEOPLE RECEIVING MODERATE, LOW OR MINIMAL EMETOGENIC CHEMOTHERAPY, ESCALATION OF TREATMENT TO THE NEXT HIGHEST LEVEL OF INTENSITY SHOULD BE UNDERTAKEN

FOR CHILDREN AND YOUNG PEOPLE RECEIVING HIGHLY EMETOGENIC CHEMOTHERAPY, ADDITION OF A) LEVOMEPRIMAZINE OR B) METOCLOPRAMIDE OR C) LORAZEPAM (SEE TABLE 3 BELOW) TO THE TREATMENT SHOULD BE CONSIDERED

REFRACTORY NAUSEA OR VOMITING

Refractory refers to the continuation of significant nausea or vomiting without a period of acceptable control. Should a child or young person experience this, a 'next level up' approach to prophylaxis should be strongly considered on subsequent cycles.

FOR CHILDREN AND YOUNG PEOPLE RECEIVING MODERATE, LOW OR MINIMAL EMETOGENIC CHEMOTHERAPY, ESCALATION OF TREATMENT TO THE NEXT HIGHEST LEVEL OF INTENSITY SHOULD BE UNDERTAKEN

FOR CHILDREN AND YOUNG PEOPLE RECEIVING HIGHLY EMETOGENIC CHEMOTHERAPY, CONSIDER SUBSTITUTION OF ONDANSETRON FOR AN ALTERNATIVE 5HT₃ ANTAGONIST, FOR EXAMPLE GRANISETRON (LICENCED IV/ORAL FOR CHILDREN AND PATCHES FOR OLDER CHILDREN AS PER BNF).

FOR CHILDREN AND YOUNG PEOPLE RECEIVING HIGHLY EMETOGENIC CHEMOTHERAPY, WHO HAVE PREVIOUSLY BEEN CONSIDERED TO HAVE A CONTRAINDICATION TO APPRENTANT, RE-VISITING THAT DECISION IS STRONGLY RECOMMENDED

FOR CHILDREN AND YOUNG PEOPLE WHO CONTINUE TO SUFFER REFRACTORY NAUSEA AND /OR VOMITING, ADDITION OF A) LEVOMEPRMAZINE INFUSION INSTEAD OF BOLUS INJECTION OR B) LORAZEPAM OR C) ACUPRESSURE TO THE TREATMENT SHOULD BE CONSIDERED

Other alternative agents and approaches have been used. For example, hyoscine patches can be used for subsequent courses for refractory emesis failing to respond to other rescue therapy, applied the night before chemotherapy is due (at least 12 hours prior to chemotherapy). Others may use nabilone for refractory cinv for adolescents. Some data suggest the use of olanzapine; this is subject to ongoing study in North America.

ANTICIPATORY NAUSEA OR VOMITING

Anticipatory refers to significant nausea or vomiting prior to the delivery of chemotherapy. Research in this area is particularly weak. Lorazepam is used with good effect in centres. Refer to dosing information below in table 4. Some centers use ondansetron and / or levomepromazine up to 24hrs prior to chemotherapy.

FOR CHILDREN AND YOUNG PEOPLE WHO DEVELOP ANTICIPATORY NAUSEA AND/OR VOMITING, PSYCHOLOGICAL INTERVENTIONS SUCH AS HYPNOSIS OR SYSTEMATIC DESENSITIZATION MAY BE OFFERED

FOR CHILDREN AND YOUNG PEOPLE WHO DEVELOP ANTICIPATORY NAUSEA AND/OR VOMITING, LOW DOSE LORAZEPAM REFER TO TABLE 4, MAY BE PRESCRIBED THE DAY BEFORE, AND FROM THE FIRST DAY OF CHEMOTHERAPY

DELAYED NAUSEA & VOMITING

The above regimens are intended to prevent both acute and delayed nausea and vomiting. If additional agents are required, then aprepitant (cisplatin based regimens), granisetron and nabilone (adolescents) can be used.

DISCHARGE MEDICATION:

For very high and high emetogenic regimes, ensure patients are discharged on at least 3 days of anti-emetics.

SOURCE GUIDELINES:

POGO Guidelines for the management of chemotherapy induced nausea and vomiting.
<http://www.pogo.ca/healthcare/practiceguidelines/>

REFERENCES TO TOOLS:

Baxter, A., Watcha, M., Baxter, W., Leong, T. and Wyatt, M. (2011) Development and Validation of a Pictorial Nausea Rating Scale for Children. *Pediatrics*, 127(6), pp.1542–1549.

Dupuis, L.L., Taddio, A., Kerr, E., Kelly, A. and MacKeigan, L. (2006) Development and Validation of the Pediatric Nausea Assessment Tool for Use in Children Receiving Antineoplastic Agents. *Pharmacotherapy*, 26(9), pp.1221-1231.

Rhodes, V. and McDaniel, R. (1999) The Index of Nausea, Vomiting, and Retching: A New Format of the Index of Nausea and Vomiting. *Oncology Nursing Forum*, 26(5), pp.889-894.

Wood, J.M., Chapman, K. and Eilers, J.(2011) Tools for Assessing Nausea, Vomiting, and Retching. *Cancer Nursing*, 34(1), E14-E24.

OTHER REFERENCES:

Dewan, P., Singhal, S. and Harit, D. (2010) Management of Chemotherapy-Induced Nausea and Vomiting. *Indian Pediatrics*, 47, pp. 149-155.


Kraukauer , E.L., Zhu, A.X., Bounds, B.C., Sahani, D., McDonald, K.R., and Brachfel, E. (2005) Case 6-2005: A 58- Year Old Man with Esophageal Cancer and Nausea and Vomiting and Intractable Hiccups. *New England Journal of Medicine*, 352(8), pp.817-825.

Navari, R. (2013) Management of Chemotherapy-Induced Nausea and Vomiting: Focus on Newer Agents and New Uses for Older Agents. *Drugs*, 73, pp.249-262.

Rodgers, C., Norville, R., Taylor, O., Poon, C., Hesselgrave, J., Gregurich, M. and Hockenberry, M. (2012) Children's Coping Strategies for Chemotherapy-Induced Nausea and Vomiting. *Oncology Nursing Forum*, 39(2), pp.202-209.

Wood, M., Hall, L., Hockenberry, M. and Borinstein, S. (2015) Improving Adherence to Evidence-Based Guidelines for Chemotherapy-Induced Nausea and Vomiting. *Journal of Pediatric Oncology Nursing*, 32(4), pp.195 –20.

FIGURE 1. SITE OF ACTIONS OF ANTI-EMETICS



Krakauer et al. (2005). *New England Journal of Medicine*, 352, 817.

TABLE. 1. SITE OF ACTIONS OF ANTI-EMETICS

	Dopamine- receptor antagonist (D ₂)	Histamine- receptor antagonist (H ₁)	Acetylcholine receptor antagonist	5- hydroxytryptam ine receptor ₃ - receptor antagonist	5- hydroxytryptam ine receptor ₂ - receptor antagonist	5- hydroxytrypta mine receptor ₄ - receptor agonist	NK1 inhibitor (NK1)
Dexamethasone				+++			
Aprepitant							+++
Cyclizine		++	++				
Hyoscine hydrobromide			+++				
Levomopromazin e	++	+++	++		+++		
Metoclopramide	++			+		++	
Ondansetron				+++			

Avoid Cyclizine and Metoclopramide together – Metoclopramide is a prokinetic (stimulates the gut) while Cyclizine slows it down. They can be used together in a palliative care scenario.

Levomopromazine covers actions of Metoclopramide, Cyclizine and Hyoscine but has a greater number of side effects.

TABLE 2. OVERALL APPROACH FLOW-CHART




TABLE 3. EMETOGENICITY OF CHEMOTHERAPY (EXAMPLE)

Very High emetogenic potential (>90%)

<p>Cisplatin</p> <p>Cyclophosphamide > 2g/m²</p> <p>Ifosfamide</p> <p>Melphalan</p> <p>Thiotepa</p> <p><i>Combination chemotherapies:</i></p> <p>Cyclophosphamide + anthracycline</p> <p>Cyclophosphamide + etoposide</p> <p>Etoposide + Ifosfamide</p> <p>Doxorubicin + Ifosfamide</p> <p>Cytarabine 300 mg/m² + etoposide</p> <p>Doxorubicin + methotrexate 5g/m²</p>	<p>Step 1: Cisplatin based regimen, ifosfamide or melphalan:</p> <p>Ondansetron IV pre chemotherapy then IV/oral regularly <i>and</i></p> <p>Dexamethasone IV/oral (if appropriate) <i>and</i></p> <p>≥6mths: Aprepitant oral ONCE daily for 3 days.</p> <p>< 6 mths:levomepromazine instead of aprepitant.</p> <p>Step 1: For non- cisplatin based regimen: Ondansetron and dexamethasone as above +/- levomepromazine (for <1yr to 17yrs)</p> <p>Step 2: Ensure all doses in step 1 have been optimised before moving onto step 2 and add Aprepitant oral if not used in step 1 for subsequent cycles - >6mths old]. Add levomepromazine for breakthrough if not given up front. See table 4 for aprepitant drug interactions and dexamethasone dose reduction.</p> <p>Delayed: give levomepromazine. Care with aprepitant and ifosfamide-see below in table 4.</p> <p>Metoclopramide can be used instead of levomepromazine for > 1 year olds.</p>
---	--

High emetogenic potential (>90%)

<p>Dactinomycin</p> <p>Carboplatin</p> <p>Carmustine>250mg/m²</p> <p>Cyclophosphamide 1g/m² - 2g/m²</p> <p>Cytarabine 3g/m²/dose</p> <p>Dacarbazine</p> <p>Methotrexate ≥12 g/m²</p>	<p>Step 1:</p> <p>Ondansetron IV pre chemotherapy then IV/oral regularly <i>and</i></p> <p>Dexamethasone IV/oral (if appropriate)</p> <p>Step 2: (Ensure all doses in step 1 have been optimised before moving onto step 2)</p> <p>Add Levomepromazine IV/oral if not used in step 1</p> <p>[add Aprepitant oral if not used in step 1 for subsequent cycles – > 6mths old]. Refer to table 4 for aprepitant drug interactions and Dexamethasone dose reduction.</p> <p>Step 3: Consider levomepromazine infusion. [Add Aprepitant oral if not used in step 1 for subsequent cycles – for > 6mths olds). Metoclopramide can be used instead of levomepromazine for > 1 year olds.</p> <p>Delayed:Dexamethasone (if appropriate) iv/oral and metoclopramide (up to 5 days after chemotherapy completed)</p>
--	---

TABLE 3 CONTINUED: EMETOGENICITY OF CHEMOTHERAPY

Moderate emetogenic potential (30-90%)

Aldesleukin	Daunorubicin	Irinotecan	<p>Step 1:</p> <p>Ondansetron IV pre chemo then IV/oral regularly +/- dexamethasone. If c/I to steroids prescribe levomepromazine instead/metoclopramide.</p> <p>Step 2:</p> <p>Add Dexamethasone (if appropriate) mostly at step 2 than step1). Then add levomepromazine IV/oral if not already added or metoclopramide</p> <p>[Consider Dexamethasone IV/oral for subsequent courses if appropriate)</p> <p>Delayed:</p> <p>Dexamethasone(if appropriate) and metoclopramide</p>
Arsenic trioxide	Daunorubicin liposomal	Lomustine	
Azacitidine	Docetaxel	Methotrexate	
Cladribine	Doxorubicin	≥1g/m ² to <12g/m ²	
Clofarabine	Etoposide	Mitoxantrone	
Cyclophosphamide	Epirubicin	Oxaliplatin>	
< 1g/m ²	Idarubicin	75mg/m ²	
Cytarabine >200mg/m ² to <3g/m ²	Imatinib	Procarbazine	
	Inotuzumab	Temozolomide	
		Treosulfan	

Low emetogenic potential (<30%)

Amsacrine	Gemtuzumab	<p>Step 1:</p> <p>Use prn Ondansetron</p> <p>Step 2:</p> <p>Ondansetron oral/IV regularly</p>
ATG	Hydroxyurea	
Bortezomib	Intrathecal	
Busulfan	Nilotinib	
Capecitabine	Paclitaxel	
CH14.18 Antibodies	Topotecan	
Cyclophosphamide <300 mg/m ²	Vinblastine/ Vincristine	
Cytarabine <200 mg/m ²	Vindesine	
Fludarabine	Vinorelbine	
5-fluorouracil		
Gemcitabine		

TABLE 3 CONTINUED: EMETOGENICITY OF CHEMOTHERAPY

Minimal emetogenic potential (min) <10%

Alemtuzumab	Methotrexate < 1g/m ²	Step 1 : No antiemetics required unless previous history of emesis. If previous history, use Ondansetron .
Asparaginase	Nelarabine	
Bevacizumab	Rituximab	
Bleomycin	Sorafenib	
Chlorambucil	Sunitinib	
Dasatinib	Temsirolimus	
Lenalidomide	Thalidomide	
Mercaptopurine	Thioguanine	

Anticipatory Nausea and Vomiting

Anticipatory refers to significant nausea or vomiting prior to the delivery of chemotherapy.	Lorazepam oral: Give one dose evening before and one dose 1 hr before starting chemotherapy
--	--

Very High

Step 1:

Cisplatin based regimen or melphalan:

Ondansetron IV pre chemotherapy then IV/PO regularly *and*

Dexamethasone IV/oral (if appropriate) *and*

<1yr-5yrs: levomepromazine

≥6mths: Aprepitant oral; ONCE daily for 3 days.

For non- cisplatin based regimen:

Ondansetron and dexamethasone as above +- levomepromazine

Step 2:

Ensure all doses in step 1 have been optimised before moving onto step 2.

add **Aprepitant oral** if not used in step 1 **for subsequent cycles – all age groups**].

Add levomepromazine for breakthrough if not given up front.

Delayed: give levomepromazine. Care with aprepitant and ifosfamide-see table 4 below.

High

Step 1:

Ondansetron IV pre chemotherapy then IV/oral regularly *and*

Dexamethasone IV/oral (if appropriate)

Step 2:

(Ensure all doses in step 1 have been optimised before moving onto step 2)

Add Levomepromazine IV/PO if not used in step 1

[add **Aprepitant oral** if not used in step 1 **for subsequent cycles – all age groups**]

Step 3:

Consider levomepromazine infusion.

[Add **Aprepitant oral** if not used in step 1 **for subsequent cycles – all age groups**]

Moderate

Step 1:

Ondansetron IV pre chemotherapy then IV/oral regularly +/- dexamethasone. If c/I to steroids prescribe levomepromazine instead.

Step 2:

Add **levomepromazine** IV/oral if not already added. Dexamethasone (if appropriate) mostly at step 2 than step1

[Consider **Dexamethasone IV/oral** for subsequent courses if appropriate)

Low/Minimum

Step 1:

No anti-emetics for minimum otherwise ondansetron prn for low

Step 2:

Ondansetron oral/IV regularly

TABLE 4. ANTI-EMETICS RECOMMENDED DOSAGES AND USAGE INSTRUCTIONS (ALPHABETICAL)

<p><u>DRUG : Aprepitant</u></p> <p>Drug class: <i>NK1 receptor antagonist</i></p> <p>Formulations: 125mg, 80mg capsule, 125mg powder for oral suspension</p> <p>INDICATION: Treat and prevent acute and delayed CINV for cisplatin regimens</p>	<p><u>Drug dose and route:</u> Administered orally 1 hour prior to chemotherapy on Days 1, 2 and 3. If no chemotherapy is given on Days 2 and 3, administer in the morning</p> <table border="1" data-bbox="542 328 1211 995"> <thead> <tr> <th>Weight</th> <th>Day 1</th> <th>Day 2</th> <th>Day 3</th> </tr> </thead> <tbody> <tr> <td><6kg</td> <td colspan="3">Not recommended for <6 months old</td> </tr> <tr> <td>6kg–7.9kg</td> <td>25mg</td> <td>15mg</td> <td>15mg</td> </tr> <tr> <td>8kg–9.9kg</td> <td>30mg</td> <td>20mg</td> <td>20mg</td> </tr> <tr> <td>10kg–11.9kg</td> <td>35mg</td> <td>25mg</td> <td>25mg</td> </tr> <tr> <td>12kg–14.9kg</td> <td>45mg</td> <td>30mg</td> <td>30mg</td> </tr> <tr> <td>15kg–19.9kg</td> <td>60mg</td> <td>40mg</td> <td>40mg</td> </tr> <tr> <td>20kg–24.9kg</td> <td>75mg</td> <td>50mg</td> <td>50mg</td> </tr> <tr> <td>25kg–29.9kg</td> <td>90mg</td> <td>60mg</td> <td>60mg</td> </tr> <tr> <td>30 kg and above</td> <td>125mg</td> <td>80mg</td> <td>80mg</td> </tr> </tbody> </table>	Weight	Day 1	Day 2	Day 3	<6kg	Not recommended for <6 months old			6kg–7.9kg	25mg	15mg	15mg	8kg–9.9kg	30mg	20mg	20mg	10kg–11.9kg	35mg	25mg	25mg	12kg–14.9kg	45mg	30mg	30mg	15kg–19.9kg	60mg	40mg	40mg	20kg–24.9kg	75mg	50mg	50mg	25kg–29.9kg	90mg	60mg	60mg	30 kg and above	125mg	80mg	80mg	<p><u>Side effects:</u> Hiccups, headache, decreased appetite, cough, neutropenia (slightly prolonged compared to without aprepitant).</p>	<p><u>Comments:</u> NB: Can increase Ifosfamide mediated neurotoxicity and Irinotecan toxicity. Monitor closely. Caution in patients receiving concomitant substances that are metabolised primarily through CYP3A4 and with a narrow therapeutic range. Also p450 2c9 inducer. Avoid aprepitant with the following:pimozide, terfenadine and St John’s Wort. Caution with the following as they may affect the aprepitant level and efficacy: ketoconazole, Itraconazole, voriconazole, posaconazole, ciclosporin,tacrolimus, sirolimus, everolimus, irinotecan and clarithromycin. Aprepitant may reduce the efficacy of warfarin. Also reduces the efficacy of hormonal contraception during and for 28 days after its use. Dose of oral dexamethasone must be reduced by 50% .</p>
Weight	Day 1	Day 2	Day 3																																								
<6kg	Not recommended for <6 months old																																										
6kg–7.9kg	25mg	15mg	15mg																																								
8kg–9.9kg	30mg	20mg	20mg																																								
10kg–11.9kg	35mg	25mg	25mg																																								
12kg–14.9kg	45mg	30mg	30mg																																								
15kg–19.9kg	60mg	40mg	40mg																																								
20kg–24.9kg	75mg	50mg	50mg																																								
25kg–29.9kg	90mg	60mg	60mg																																								
30 kg and above	125mg	80mg	80mg																																								

<p><u>Drug: Cyclizine</u></p> <p>Drug class: <i>Antihistamine</i></p> <p>Formulations: 50mg tablets, IV injection</p> <p>INDICATION: For the purpose of this guidelines use for emesis of raised intracranial pressure. Palliative care, irradiation sickness and opiate induced vomiting.</p>	<p><u>Drug dose and route:</u></p> <p>IV/Oral:</p> <table border="1" data-bbox="542 225 1453 523"> <tr> <td>1 month–5 years</td> <td>500microgram-1mg/kg up to 3 times daily (Max 25mg/dose) Prescribe to the nearest 5mg.</td> </tr> <tr> <td>6–11 years</td> <td>25mg up to 3 times daily</td> </tr> <tr> <td>12 years+</td> <td>50 mg up to 3 times daily</td> </tr> </table> <p>Continuous IV or SC Infusion:</p> <table border="1" data-bbox="542 592 1283 855"> <tr> <td>1–23 months</td> <td>3mg/kg over 24 hours</td> </tr> <tr> <td>2–5 years</td> <td>50mg over 24 hours</td> </tr> <tr> <td>6–11 years</td> <td>75mg over 24 hours</td> </tr> <tr> <td>12–17 years</td> <td>150mg over 24 hours</td> </tr> </table>	1 month–5 years	500microgram-1mg/kg up to 3 times daily (Max 25mg/dose) Prescribe to the nearest 5mg.	6–11 years	25mg up to 3 times daily	12 years+	50 mg up to 3 times daily	1–23 months	3mg/kg over 24 hours	2–5 years	50mg over 24 hours	6–11 years	75mg over 24 hours	12–17 years	150mg over 24 hours	<p><u>Side effects:</u></p> <p>Drowsiness, Dry mouth</p> <p>Blurred vision</p> <p>Urinary retention</p> <p>Restlessness</p> <p>Insomnia, Tachycardia</p> <p>Drug induced rash</p> <p>Extrapyramidal side effects rare</p>	<p><u>Comments:</u></p> <p>Avoid using with Hyoscine and Levomepromazine</p> <p>For continuous IV or SC infusion – dilute with Glucose 5%, water for injection or normal saline0.9%.</p> <p>Crush the tablets and disperse in water prior to administration.</p>
1 month–5 years	500microgram-1mg/kg up to 3 times daily (Max 25mg/dose) Prescribe to the nearest 5mg.																
6–11 years	25mg up to 3 times daily																
12 years+	50 mg up to 3 times daily																
1–23 months	3mg/kg over 24 hours																
2–5 years	50mg over 24 hours																
6–11 years	75mg over 24 hours																
12–17 years	150mg over 24 hours																

<p><u>Drug: Dexamethasone</u></p> <p>Drug class: <i>Corticosteroid</i></p> <p>Formulations: 2mg tablets/2mg soluble tablet 0.5mg tablets 2mg/5mL liquid IV injection</p> <p>Indication: Effective for delayed emesis and acute CINV</p>	<p><u>Drug dose and route:</u></p> <p>IV/Oral:</p> <p>Loading dose 8mg/m² (Max single dose 12mg). Then:</p> <table border="1" data-bbox="544 355 981 619"> <thead> <tr> <th>SA m²</th> <th>IV/Oral Dose</th> </tr> </thead> <tbody> <tr> <td>≤ 0.6m²</td> <td>2mg TWICE a day</td> </tr> <tr> <td>> 0.6m²</td> <td>4mg TWICE a day</td> </tr> <tr> <td>>1.2m²</td> <td>8mg TWICE a day</td> </tr> </tbody> </table> <p>Or prescribe 2.5mg-5mg/m² up to Three times a day</p> <p>Prescribe TWICE daily doses early morning and afternoon to reduce insomnia (E.g. 5am and 4pm). Frequency can be increased to TDS.</p>	SA m ²	IV/Oral Dose	≤ 0.6m ²	2mg TWICE a day	> 0.6m ²	4mg TWICE a day	>1.2m ²	8mg TWICE a day	<p><u>Side effects:</u></p> <p>Adrenal suppression</p> <p>Gastric irritation</p> <p>Osteoporosis</p> <p>Weight gain, insomnia</p> <p>Mood and behavioural problems</p>	<p><u>Comments:</u></p> <p>Give 1st dose with Ondansetron, before chemotherapy. For maximum of 5 days</p> <p>IV Dose should be infused.</p> <p>Dose of dexamethasone must be halved when used in combination with Aprepitant.</p> <p>Contra-indicated: Brain tumour patients and those already on steroids (allogenic BMT, SCT, and ALL) & those on mifamurtide. Caution in osteosarcoma patients (discuss with the consultant).</p>
SA m ²	IV/Oral Dose										
≤ 0.6m ²	2mg TWICE a day										
> 0.6m ²	4mg TWICE a day										
>1.2m ²	8mg TWICE a day										
<p><u>Drug:Granisetron</u></p> <p><u>patch 3.1mg/24 hours</u></p> <p>Indication: treat and prevent acute and delayed CINV</p>	<p><u>Drug dose and route:</u></p> <p>12 years -18yrs</p> <p>Apply 1 patch 24-48 hrs. Before chemotherapy due.</p> <p>Iv and oral doses for granisetron for those trusts still able to prescribe as per BNFC</p>	<p><u>Side effects:</u></p> <p>Constipation, headache, rash.</p> <p>Transient increase in liver enzymes.</p>	<p><u>Comments:</u></p> <p>Patch can be kept on for 7 days</p> <p>Remove at least 24 hours after chemotherapy has been completed.</p> <p>Not licensed in children Only consider for nausea and vomiting induced by cytotoxic chemotherapy for planned duration of 3–5 days where oral antiemetics cannot be used.</p>								

<p><u>Drug:</u></p> <p><u>Hyoscine</u> <u>Hydrobromide</u></p> <p>Drug class:</p> <p><i>Anticholinergic/Antimuscarinic</i></p> <p>Formulations:</p> <p>Transdermal Patch 1mg/72 hrs.</p> <p>Indication: refractory CINV</p>	<p><u>Drug dose and route:</u></p> <p>Topically:</p> <p>Will take up to 6 hours to work</p> <table border="1" data-bbox="544 292 1245 491"> <tr> <td>1 month – 2 years</td> <td>1/4 of a patch every 72 hours</td> </tr> <tr> <td>3 – 9 years</td> <td>1/2 of a patch every 72 hours</td> </tr> <tr> <td>10 years+</td> <td>1 patch every 72 hours</td> </tr> </table>	1 month – 2 years	1/4 of a patch every 72 hours	3 – 9 years	1/2 of a patch every 72 hours	10 years+	1 patch every 72 hours	<p><u>Side effects:</u></p> <p>Drowsiness</p> <p>Dry mouth</p> <p>Dizziness</p> <p>Blurred vision</p> <p>Difficulty with micturition</p>	<p><u>Comments:</u></p> <p>Avoid using with Cyclizine, metoclopramide and Levomepromazine</p> <p>Apply to a clean, dry, hairless area of skin behind the ear, avoiding any cuts or irritation. Wash hands after applying and the skin area after removal.</p> <p>Scopaderm® patches can be cut.</p>
1 month – 2 years	1/4 of a patch every 72 hours								
3 – 9 years	1/2 of a patch every 72 hours								
10 years+	1 patch every 72 hours								

<p>Drug:</p> <p><u>Levomepromazine</u></p> <p>Drug class:</p> <p><i>Phenothiazine</i></p> <p>Formulations:</p> <p>6mg tablet, 25mg Tablets</p> <p>(tablets may be halved and dispersed)</p> <p>IV Injection</p> <p>Indication:</p> <p>Delayed emesis, refractory and breakthrough CINV</p> <p>Useful in vomiting due to raised intracranial pressure</p>	Drug dose and route:		Side effect:	Comments:	
	Oral				Somnolence Asthenia Dry mouth Hypotension Sedation Site reaction constipation
	1 month – 11 years	<p>50-200microgram/kg once or twice a day.</p> <p>Dose may be increased as necessary and as tolerated.</p> <p>Max 1mg/kg/dose once or twice a day (max 25mg/dose)</p>			
	12-17 years	<p>3- 6.25 mg once or twice a day.</p> <p>Dose may be increased as necessary and as tolerated.</p> <p>Max 25 mg twice daily.</p>			
	Dose rounding	<p>Dose doses less than 3mg – Prescribe to the nearest 0.5mg. Disperse one 6mg tablet in 6mL of water and give proportion.</p> <p>Doses greater than 3mg – round to nearest 3mg or 12.5mg. Liquid can be manufactured in some centers.</p>			
	<p>Important as no liquid formulation available</p>				
	Slow IV Infusion: over 30 minutes				
	<p>25-100microgram/kg TWICE daily or daily</p>				
	Continuous IV or SC Infusion:				
	1 month – 11 years	<p>Continuous infusion 100-400microgram/kg in 24 hrs.</p> <p>Maximum 25mg/24 hours</p>			
12-17 years	<p>5mg to 25mg over 24 hours increasing as necessary to a max of 25mg/24 hours</p>				

<u>Drug:</u>	<u>Drug dose and route:</u>	<u>Side effects:</u>	<u>Comments:</u>
<p data-bbox="165 188 338 220"><u>Lorazepam</u></p> <p data-bbox="165 264 282 288">Drug class:</p> <p data-bbox="165 328 338 352"><i>Benzodiazepine</i></p> <p data-bbox="165 392 315 416">Formulations:</p> <p data-bbox="165 456 517 520">1mg & 2mg tablets (tablets may be halved), IV Injection</p> <p data-bbox="165 560 282 584">Indication:</p> <p data-bbox="165 624 517 719">Anticipatory nausea and vomiting. Breakthrough and refractory CINV.</p>	<p data-bbox="546 169 757 193">Slow IV bolus/Oral:</p> <p data-bbox="546 233 1200 256">50microgram-100microgram/kg (max 4mg) every 8–12 hours</p> <p data-bbox="546 360 1458 424">For anticipatory nausea and vomiting, give one dose evening before and one dose 1 hour before starting chemotherapy.</p>	<p data-bbox="1487 169 1608 193">Drowsiness</p> <p data-bbox="1487 233 1581 256">Amnesia</p> <p data-bbox="1487 296 1659 360">Confusion and ataxia</p> <p data-bbox="1487 400 1659 464">Pain with IV injection</p>	<p data-bbox="1695 169 2074 264">Care in patients receiving ifosfamide since sedation may mask signs of encephalopathy</p>

<p>Drug:</p> <p><u>Metoclopramide</u></p> <p>Drug class:</p> <p><i>Dopamine antagonist</i></p> <p>Formulations:</p> <p>10mg Tablets</p> <p>5mg/5mL liquid</p> <p>10mg/2ml Injection</p> <p>Indication:</p> <p>Prevent delayed nausea and vomiting. Effective for severe intractable vomiting due to radiotherapy.</p>	<p>Drug dose and route:</p> <p>IV/Oral: Prevention of delayed chemotherapy-induced nausea and vomiting</p> <p>150microgram/kg THREE times a day – dose banded as per below</p> <p>Prescribe for as short a duration as possible and review regularly</p> <p>Contraindicated in children <1 year Maximum 10mg per dose TDS. See MHRA alert 2013. Consultant decision.</p> <table border="1" data-bbox="542 523 1075 917"> <thead> <tr> <th>Weight</th> <th>Oral Dose</th> <th>IV Dose</th> </tr> </thead> <tbody> <tr> <td>10–14.9kg</td> <td>1mg</td> <td>1mg</td> </tr> <tr> <td>15–19.9kg</td> <td>2mg</td> <td>2mg</td> </tr> <tr> <td>20–29.9kg</td> <td>2.5mg</td> <td>2.5mg</td> </tr> <tr> <td>30–60kg</td> <td>5mg</td> <td>5mg</td> </tr> <tr> <td>>60kg</td> <td>10mg</td> <td>10mg</td> </tr> </tbody> </table>	Weight	Oral Dose	IV Dose	10–14.9kg	1mg	1mg	15–19.9kg	2mg	2mg	20–29.9kg	2.5mg	2.5mg	30–60kg	5mg	5mg	>60kg	10mg	10mg	<p>Side effects:</p> <p>Extrapyramidal effects</p> <p>Hyperprolactinemia</p> <p>Drowsiness</p> <p>Restlessness</p>	<p>Comments:</p> <p>Should be used after levomepromazine failed for maximum 5-days. Review with consultant before using.</p> <p>Reduce dose in renal and hepatic impairment</p> <p>Use with caution with cyclizine and hyoscine – will reduce prokinetic effects</p> <p>Treat dystonic reactions with IV bolus of PROCYCLIDINE:</p> <table border="1" data-bbox="1693 746 2063 922"> <tbody> <tr> <td><2 yrs.</td> <td>0.5-2mg as a single dose</td> </tr> <tr> <td>2–10 yrs.</td> <td>2-5mg as a single dose</td> </tr> <tr> <td>>10 yrs.</td> <td>5-10mg as a single dose</td> </tr> </tbody> </table> <p>Usually effective in 5-10 min but may take up to 30min</p>	<2 yrs.	0.5-2mg as a single dose	2–10 yrs.	2-5mg as a single dose	>10 yrs.	5-10mg as a single dose
Weight	Oral Dose	IV Dose																									
10–14.9kg	1mg	1mg																									
15–19.9kg	2mg	2mg																									
20–29.9kg	2.5mg	2.5mg																									
30–60kg	5mg	5mg																									
>60kg	10mg	10mg																									
<2 yrs.	0.5-2mg as a single dose																										
2–10 yrs.	2-5mg as a single dose																										
>10 yrs.	5-10mg as a single dose																										

<p><u>Drug:</u></p> <p><u>Nabilone</u></p> <p><u>Preparations:</u></p> <p>Capsule 1mg</p> <p><u>Indication:</u> For delayed and refractory CINV in adolescents.</p>	<p><u>Drug dose and route:</u></p> <p>Oral >30kg 1mg three times a day</p>	<p><u>Side effects:</u></p> <p>dizziness, drowsiness, behavioral alterations, dry mouth, ataxia, postural hypotension. Hallucinations, euphoria and other psychotic reactions in some patients. Patients and carers should be made aware of possible changes in mood and other adverse behavioural effects.</p>	<p><u>Comments:</u></p> <p>A cannabinoid drug with central action.</p> <p><u>Used</u> in adolescents when refractory to dexamethasone and ondansetron.</p> <p>It is used for acute, delayed and refractory emesis.</p> <p>Used for high & very high when 1st, 2nd & 3rd line failed for subsequent cycles.</p> <p>Start the night before, duration of chemo and until 48 hours after chemo.</p> <p>Do not use with levomepromazine and lorazepam.</p>
---	--	--	---

<p><u>Drug:</u></p> <p><u>Ondansetron</u></p> <p>Drug class:</p> <p><i>5HT₃ antagonist</i></p> <p>Formulations:</p> <p>4mg tablets</p> <p>8mg tablets</p> <p>4mg/8mg orodispersible film*</p> <p>4mg/5mL liquid</p> <p>IV 2mg/ml</p> <p>Sublingual melts:4mg&8mg</p>	<p><u>Drug dose and route:</u></p> <p>IV/Oral:</p> <p>5mg/m² TWICE TO THREE times a day (Max 8mg per dose) – dose banding can be used in your trust as per below</p> <table border="1" data-bbox="636 373 1364 1032"> <thead> <tr> <th>Weight</th> <th>SA m²</th> <th>Oral Dose</th> <th>IV Dose</th> </tr> </thead> <tbody> <tr> <td>4–4.9kg</td> <td>0.26–0.29</td> <td>1mg</td> <td>1.5mg</td> </tr> <tr> <td>5–6.9kg</td> <td>0.30–0.37</td> <td>2mg</td> <td>1.5mg</td> </tr> <tr> <td>7–8.9kg</td> <td>0.38–0.45</td> <td>2mg</td> <td>2mg</td> </tr> <tr> <td>9–11.9kg</td> <td>0.46–0.55</td> <td>2mg</td> <td>2.5mg</td> </tr> <tr> <td>12–16.9kg</td> <td>0.56–0.70</td> <td>4mg</td> <td>3mg</td> </tr> <tr> <td>17–23.9kg</td> <td>0.71–0.89</td> <td>4mg</td> <td>4mg</td> </tr> <tr> <td>24–29.9kg</td> <td>0.9–1.09</td> <td>4mg</td> <td>5mg</td> </tr> <tr> <td>30–38.9kg</td> <td>1.1– 1.2</td> <td>6mg</td> <td>6mg</td> </tr> <tr> <td>>39</td> <td>>1.2</td> <td>8mg</td> <td>8mg</td> </tr> </tbody> </table>	Weight	SA m ²	Oral Dose	IV Dose	4–4.9kg	0.26–0.29	1mg	1.5mg	5–6.9kg	0.30–0.37	2mg	1.5mg	7–8.9kg	0.38–0.45	2mg	2mg	9–11.9kg	0.46–0.55	2mg	2.5mg	12–16.9kg	0.56–0.70	4mg	3mg	17–23.9kg	0.71–0.89	4mg	4mg	24–29.9kg	0.9–1.09	4mg	5mg	30–38.9kg	1.1– 1.2	6mg	6mg	>39	>1.2	8mg	8mg	<p><u>Side effects:</u></p> <p>Constipation</p> <p>Headache</p> <p>Flushing</p> <p>Occasional diarrhea</p>	<p><u>Comments:</u></p> <p>*Use Orodispersible film if possible as it is cheaper than liquid ondansetron for patients with SA >0.56m² or wt. >12kg.</p> <p>Each film is a 4mg dose and it cannot be halved.</p> <p>Reduce dose in moderate or severe hepatic impairment</p> <p>Do not use with drugs that prolong QT interval</p> <p>Less effective for delayed emesis use metoclopramide</p>
Weight	SA m ²	Oral Dose	IV Dose																																								
4–4.9kg	0.26–0.29	1mg	1.5mg																																								
5–6.9kg	0.30–0.37	2mg	1.5mg																																								
7–8.9kg	0.38–0.45	2mg	2mg																																								
9–11.9kg	0.46–0.55	2mg	2.5mg																																								
12–16.9kg	0.56–0.70	4mg	3mg																																								
17–23.9kg	0.71–0.89	4mg	4mg																																								
24–29.9kg	0.9–1.09	4mg	5mg																																								
30–38.9kg	1.1– 1.2	6mg	6mg																																								
>39	>1.2	8mg	8mg																																								

Drug:	<u>Drug dose and route:</u>	<u>Side effects:</u>	<u>Comments:</u>
<p data-bbox="165 183 358 220"><u>Procyclidine</u></p> <p data-bbox="165 260 331 288">Anticholinergic</p> <p data-bbox="165 323 517 389">Prevent & treat acute dystonic reactions</p> <p data-bbox="165 427 304 456">Preparation:</p> <p data-bbox="165 491 353 520">5mg/ml injection</p> <p data-bbox="165 555 495 584">5mg/5ml liquid SF, 2.5mg/5ml</p> <p data-bbox="165 619 286 647">5mg tablet</p>	<p data-bbox="546 164 658 193"><u>Dystonias:</u></p> <p data-bbox="546 228 831 256">7-12 years 1.25mg 8hourly</p> <p data-bbox="546 292 819 320">>12-18yrs 2.5mg 8 hourly</p> <p data-bbox="546 427 927 456"><u>Acute dystonia doses: single doses</u></p> <p data-bbox="546 491 853 520">< 2yrs 500microgram to 2mg</p> <p data-bbox="546 555 712 584">2-10 yrs. 2-5mg</p> <p data-bbox="546 619 719 647">>10 yrs. 5-10mg</p>	<p data-bbox="1487 164 1659 193">Anti-cholinergic</p>	<p data-bbox="1695 164 2076 229">Effective in 5-10mins but may take up to 30 mins</p> <p data-bbox="1695 264 2076 371">Contra-indicated in Gastro-intestinal obstruction; myasthenia gravis. Caution in liver impairment</p>